



---

## Uploaded to VFC Website

▶▶ **November 2012** ◀◀

---

This Document has been provided to you courtesy of Veterans-For-Change!

Feel free to pass to any veteran who might be able to use this information!

For thousands more files like this and hundreds of links to useful information, and hundreds of "Frequently Asked Questions, please go to:

[Veterans-For-Change](#)

---

*Veterans-For-Change is a 501(c)(3) Non-Profit Corporation  
Tax ID #27-3820181*

***If Veteran's don't help Veteran's, who will?***

We appreciate all donations to continue to provide information and services to Veterans and their families.

[https://www.paypal.com/cgi-bin/webscr?cmd=\\_s-xclick&hosted\\_button\\_id=WGT2M5UTB9A78](https://www.paypal.com/cgi-bin/webscr?cmd=_s-xclick&hosted_button_id=WGT2M5UTB9A78)

---

**Note:**

VFC is not liable for source information in this document, it is merely provided as a courtesy to our members.



**Item ID Number** 05412



**Not Scanned**

**Author**

**Corporate Author** United States District Court, Eastern District of New Yor

**Report/Article Title** United States District Court, Eastern District of New York In re: "Agent Orange" Product Liability Litigation, Before Honorable George C. Pratt, U. S. C. J, MDL No. 381

**Journal/Book Title**

**Year** 1983

**Month/Day** May 12

**Color**



**Number of Images** 0

**Description Notes** Judge Pratt's decision. Also included is a letter from Stanley Pierce to Alvin L. Young regarding the decision. See item 5414 for pretrial order no. 51.

LAW OFFICES  
**RIVKIN, LEFF, SHERMAN & RADLER**  
100 GARDEN CITY PLAZA  
GARDEN CITY, NEW YORK 11530

TELEPHONE      TELEX      CABLE ADDRESS      TELECOPIER      SUITE 3900-30 NORTH LA SALLE STREET  
(516) 746-7500    645-074      AT LAW GRCY      (516) 747-2843    CHICAGO, ILLINOIS 60602 • (312) 782-5680

WRITERS DIRECT DIAL: (516) 228-4318

May 19, 1983

Lt. Col. Alvin Young, Ph.D.  
Agent Orange Projects Office,  
Symbol: 10A7B  
810 Vermont Avenue, N.W.  
Washington, D.C. 20420


Dear Al:

Enclosed please find a copy of Judge Pratt's decision of May 12, 1983, as per your request. At present, we plan to move for reargument, and when we do so, I will send our memorandum in support, albeit due to a protective order in respect to this case, it will probably be a redacted reversion.

Once again, thanks for the information you provided, and please do not forget me when ACS accepts your article on the A/O registry. By all means, call me when you are in New York on June 1 - 3. I would love the opportunity to return the hospitality that you have shown me in the past.

With my warmest person regards, I am

Very truly yours,

  
Stanley Pierce, J.D., Ph.D. (Biology)

SP/rr  
enc

1 UNITED STATES DISTRICT COURT  
2 EASTERN DISTRICT OF NEW YORK

3 ----- X  
4 In re: :  
5 "AGENT ORANGE" :  
6 Product Liability Litigation :  
7 ----- X

MDL No. 381

9 United States Courthouse  
10 Uniondale, Long Island  
New York

11 May 12, 1983  
12 2:25 o'clock P.M.

15 B E F O R E :

16 HONORABLE GEORGE C. PRATT, U.S.C.J.  
17

18  
19  
20  
21 HARRY RAPAPORT  
22 HENRY SHAPIRO  
23 SHELDON SILVERMAN  
Official Court Reporters  
24  
25

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
A P P E A R A N C E S :

YANNACONE & ASSOCIATES, ESQS.  
Post Office Drawer 109  
Patchogue, New York 11772

BY: VICTOR YANNACONE, ESQ.  
EUGENE J. O'BRIEN, ESQ.  
DAVID J. DEAN, ESQ.  
EDWARD J. GORMAN, ESQ.  
IRVING LIKE, ESQ.  
JOSEPH COVELLO, ESQ.  
ALBERT J. FIORELLA, ESQ.  
AARON TWERSKI, ESQ.  
WILLIAM F. LEVINE, ESQ.  
STEVEN J. SCHLEGEL, ESQ.  
JULES OLSMAN, ESQ.  
ANTHONY FALANGA, ESQ.  
JAMES A. HENDERSON, JR., ESQ.  
CLAYTON P. GILLETTE, JR., ESQ.

ASHCRAFT & GEREL, ESQS.  
2000 L Street, N. W.  
Washington, D. C. 20038

BY: ROBERT A. TAYLOR, JR., ESQ.  
JAMES F. GREEN, ESQ.  
ROBERT B. ADAMS, ESQ.

continued...

1  
2 A P P E A R A N C E S : (continued)  
3

4 RIVKIN, LEFF, SHERMAN & RADLER, ESQS.  
Attorneys for Dow Chemical  
5 100 Garden City Plaza  
Garden City, New York 11530

6 BY: LEONARD RIVKIN, ESQ.  
7 MARJORIE MINTZER, ESQ.  
STANLEY PIERCE, ESQ.  
8 LESLIE R. BENNETT, ESQ.  
BRUCE J. COHEN, ESQ.  
9 WILLIAM F. CAVANAUGH, ESQ.  
JEFFREY SILBERFIELD, ESQ.

10  
11 CHARLES CAREY, ESQ.  
12 Co-Counsel for Dow Chemical

13  
14  
15 CADWALADER, WICKERSHAM & TAFT, ESQS.  
Attorneys for Defendant Diamond Shamrock  
16 One Wall Street  
New York, New York 10005

17 BY: MICHAEL GORDON, ESQ.  
18 GEORGE D. REYCRAFT, ESQ.  
JEANNE P. BOLGER, ESQ.

19  
20 EDWARD J. MASEK, ESQ.  
General Counsel, Law Department  
21 Industrial Chemicals Unit  
22 351 Phelps Court, P. O. Box 2300  
Irving, Texas 75061

23  
24 continued...

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

A P P E A R A N C E S : (continued)

TOWNLEY & UPDIKE, ESQS.  
Attorneys for Defendant Monsanto Company  
405 Lexington Avenue  
New York, New York 10017

BY: PHILIP PAKULA, ESQ.  
JAMES E. TYRRELL, ESQ.  
JOHN C. SABETTA, ESQ.  
ROBIN STALBOW, ESQ.  
BRUCE G. SHEFFLER  
BARBARA ROTH, ESQ.  
BEVERLY ROSENBAUM, ESQ.

ROBERT T. BERENDT, ESQ.  
Litigation Counsel  
800 N. Lindbergh Boulevard  
St. Louis, Missouri 63166

CLARK, GAGLIARDI & MILLER, ESQS.  
Attorneys for Defendant T.H. Agriculture &  
Nutrition Co., Inc.  
The Inns of Court  
99 Court Street  
White Plains, New York 10607

BY: MORTON SILBERMAN, ESQ.  
JOHN J. BURKE, ESQ.  
LAWRENCE T. D'ALOISE, ESQ.

continued...

1  
2 A P P E A R A N C E S : (continued)  
3

4 KELLEY, DRYE & WARREN, ESQS.  
5 Attorneys for Defendant Hercules, Inc.  
6 101 Park Avenue  
7 New York, New York 10178

8 BY: WILLIAM A. KROHLEY, ESQ.  
9 WILLIAM HECK, ESQ.  
10

11  
12 ARTHUR, DRY & KALISH, P.C.  
13 Attorneys for Defendant Uniroyal  
14 1230 Avenue of the Americas  
15 New York, New York 10020

16 BY: THOMAS A. BECK, ESQ.  
17 MARILYN NEIMAN, ESQ.

18 -and-

19 SHEA, GOULD, ESQS.  
20 Attorneys for Uniroyal  
21 330 Madison Avenue  
22 New York, New York 10017

23 BY: RICHARD GOLDSTEIN, ESQ.  
24

25 continued...



1  
2 A P P E A R A N C E S : (continued)

3 BUDD, LARNER, KENT, GROSS, PICILLO & ROSENBAUM, ESQS.  
4 Attorneys for Defendant Thompson Chemicals  
5 33 Washington Street  
Newark, New Jersey 07102

6 BY: EDWIN R. MATTHEWS, ESQ.  
7 DAVID GROSS, ESQ.  
8  
9

10 DILWORTH, PAXON, KALISH & KAUFFMAN, ESQS.  
11 Attorneys for Defendant Hooker Chemical  
12 2600 The Fidelity Building  
Philadelphia, Pennsylvania 19109

13 BY: JOHN M. FITZPATRICK, ESQ.  
14

15 -and-

16 CHARLES E. FOSTER, ESQ.  
17 10889 Wilshire Boulevard  
18 Los Angeles, California  
19 (counsel for Hooker Chemical)  
20  
21

22 continued...  
23  
24  
25

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

## A P P E A R A N C E S : (continued)

LESTER, SCHWAB, KATZ & DWYER, ESQS.  
Attorneys for Defendant Hoffman-Taff, Inc.,  
a Missouri Corporation  
120 Broadway  
New York, New York 10271

BY: STUART AXE, ESQ.  
HOWARD LESTER, ESQ.

UNITED STATES OF AMERICA  
Civil Division, Department of Justice  
521 12th Street, Northwest  
Room 822  
Washington, D. C. 20530

BY: ARVIN MASKIN, ESQ.  
GRETCHEN LEAH WITT, ESQ.

o0o

HR/an  
1pm/1A F T E R N O O N      S E S S I O N

2  
3 THE COURT: I apologize for keeping you waiting.  
4 I was trying to do a few last minute adjustments  
5 on the grammar of what I'm about to place on the  
6 record.

7 I have reviewed the motions and I am prepared  
8 to announce a formal decision. The reason I am  
9 doing it orally rather than by a written decision  
10 is primarily for purposes of saving time. I expect  
11 for historical purposes, that I will have published  
12 a condensed version of what I am about to put on the  
13 record. But if I were to be driven at this point to  
14 polish the matters up to the point of a formal written  
15 decision presently suitable for publication I am  
16 afraid that I wouldn't have it ready for you or be  
17 able to have it ready for you until at the earliest  
18 early next week.

19 So the decision that I make with respect to the  
20 seven motions for summary judgment that were heard  
21 here last Wednesday, a week ago Wednesday, is the  
22 following:

23 In this action referred to me by the Multi  
24 District Litigation Panel under MDL docket number  
25 381, thousands of veterans and their relatives seeking

1  
2 to recover damages from nine chemical companies,  
3 Dow, Hercules, Monsanto, Diamond Shamrock, Hoffman-Taff,  
4 Thompson Chemical, Thompson Hayward, Riverdale and  
5 UniRoyal, for injuries suffered as a result of an  
6 exposure to a herbicide called Agent Orange used by  
7 military in Vietnam.

8 As the action has been contoured the claims of the  
9 plaintiffs have focused on Dioxin as a contaminant  
10 in the Agent Orange supplied to the Government under  
11 contract with the separate chemical companies.

12 By pretrial order number 26 dated September  
13 26, 1980, I recognize the possibility of a Government  
14 contract defense to the plaintiffs' claims.  
15 The contours of that defense were developed in more  
16 detail in pretrial order number 33, dated February 24,  
17 1982. Because the issues presented by the Government  
18 contract defense seemed to be separate and distinct  
19 from the general theories of liability then being  
20 advanced by plaintiffs I ordered a separate trial  
21 of the defense begin on June 27th of this year.

22 After about eleven months of extensive discovery  
23 I permitted any defendant who so elected to move  
24 for summary judgment with respect to the Government  
25 contract defense issues. The basis of such summary

1 judgment would, of course, be that there were no  
2 triable issues of fact with respect to the defense  
3 and that the moving defendant was therefore entitled  
4 as a matter of law to have all claims against it  
5 dismissed.

6 All defendants but Monsanto and Diamond Shamrock  
7 moved for summary judgment.

8 (continued on following page.)  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

1am2 hrms 1  
2 THE COURT: (Continuing) I have reviewed all  
3 of the papers submitted both in support of and in  
4 opposition to the motion, including counse's  
5 extensive memoranda. I listened closely to the oral  
6 arguments presented to me last Wednesday, May 4, 1983,  
7 and I am not prepared to place my decision on the  
8 record.

9 The central issue in the government contract  
10 defense focuses on its third element, whether the  
11 government knew as much as or more than the contracting  
12 defendant about the hazards to people and accompanied  
13 use of Agent Orange.

14 In the context of plaintiffs' claims as they  
15 have developed here, the knowledge in question is  
16 knowledge about dioxin. Thus, to focus on this  
17 element, it is necessary to compare what knowledge  
18 the government had about dioxin and about its  
19 contamination of Agent Orange with what knowledge  
20 each of the moving defendants had about these matters.

21 First I will discuss the knowledge of the  
22 government.

23 Even when all doubts are resolved in favor  
24 of the plaintiffs as required by SEC v. The Research  
25 Automation Corp., 585 F. 2d 31, the record demonstrates

1  
2 that the government and the military had a considerable  
3 amount of knowledge about 2,4,5-T, about dioxin and  
4 about the health hazards associated with both. The  
5 following general chronology, while not all inclusive,  
6 gives some indication of both the extent and the  
7 continually increasing level of government knowledge  
8 in this area:

9 As to the 1940s, during World War II the  
10 military discovered the herbicidal properties of  
11 2,4,5-T and conducted extensive testing of various  
12 possible herbicides. This research was done under  
13 the supervision of the Crops Division of the Army  
14 Chemical Corps at Camp Dietrick, Maryland.

15 In 1949 Dr. Donald Birmingham of the Public  
16 Health Service visited Nitro, West Virginia, where  
17 there had been an explosion of the Monsanto 2,4,5-T  
18 plant. The report of Dr. Birmingham's colleague,  
19 Dr. Schwartz, indicated a connection between chloracne  
20 and the chemicals produced in the plant.

21 As to the 1950s, during that period there is  
22 uncontradicted evidence in the record that a number  
23 of people knew that dioxin was toxic, although they  
24 may not have connected it with 2,4,5-T. Several  
25 factors contributed to this awareness.

1  
2           In the early 1950s C.H. Boehringer-Sohn Company  
3 of Germany had serious problems of chloracne among  
4 workers engaged in the production of trichlorophenol,  
5 a precursor chemical used in the manufacture of  
6 2,4,5-T. For convenience I will refer to this  
7 precursor chemical as TCT. By 1959 the Boehringer Sohn  
8 Company was forced to halt production at two plants.  
9 Dr. H.K. Schulz, a skin specialist, investigated the  
10 problem and in 1957, together with Professor Kimmig,  
11 reported his findings in an article entitled Chlori-  
12 nated Aromatic Cyclic Ethers as the cause of chloracne.  
13 In this article the author stated they were able to  
14 isolate dioxin which they believed to be the contaminant  
15 in TCP that was causing the health problems.

16           While it is not established that anyone in the  
17 government read the Kimmig and Schulz article at the  
18 time it was published the article was available as  
19 part of the scientific literature and it was referred  
20 to in the report written by Frederick Hoffman on his  
21 trip to Europe in 1959.

22           Dr. Hoffman, who was searching for potential  
23 chemical warfare agents, reported that he had  
24 received what he called startling information  
25 regarding the toxicity of the compound dioxin.



1  
2           In his report he described the deaths of several  
3 workers in a plant manufacturing wood preservatives  
4 which contained trace amounts of dioxin. In addition  
5 he reported that the compound could cause severe,  
6 indeed fatal liver damage.

7           At least ten copies of the Hoffman report were  
8 sent to Edgewood Arsenal, the government body respon-  
9 sible for investigating toxicity and analyzing chemical  
10 agents. Thus the Hoffman report on dioxin, coupled  
11 with the Kimmig and Schulz article connecting dioxin  
12 to TCP, raises a strong possibility that personnel  
13 Edgewood were aware even before 1960 of the connection  
14 between dioxin and TCP, as well as the use of TCP  
15 to make 2,4,5-T.

16                   (Continued on following page)

17  
18  
19  
20  
21  
22  
23  
24  
25

HR/an  
1pm/3

1 In addition, deposition testimony of Edgewood  
2 personnel confirms that people at Edgewood knew about  
3 the toxicity of Dioxin. Dr. Jandorf testified  
4 that people at Edgewood were familiar with this fact  
5 since the late 1950's. Dr. Horton testified that he  
6 knew Dioxin was toxic in 1959 as did Dr. Simmons.

7 Mr. Sultan testified that he had read the  
8 Hoffman report.

9 Further evidence of knowledge by Government  
10 personnel is found in the article written by Dr.  
11 Birmingham of the Public Health Service in 1959  
12 stating that in the manufacture of 2,4,5-T

13 ~~intermediate hydrocarbons~~ of the chlorine group had  
14 caused chloracne in more than 200 chemical workers  
15 at a manufacturing plant, presumably Monsanto's.

16 Dr. Marcus Key of the Public Health Service  
17 testified that he had learned of the association  
18 between hydrocarbons and chloracne and other diseases  
19 that the Harvard School of Public Health in 1953.

20 In the early 1960's Dr. McNamara performed  
21 a study at Edgewood Arsenal of the toxicity of  
22 Agent Purple, which was another defoliant containing  
23 2,4,5-T that was used by the military.

24 This testing was conducted at the request of  
25 General Delmore, Commanding General, U. S. Army Chemical Corps,

1 Research and Development Committee.

2 While the testing indicated there was some  
3 toxicity the results were not conclusive.

4 At a meeting held at Edgewood Arsenal in 1963  
5 to discuss and evaluate the toxicity of 2,4,5-T  
6 the overall thrust of those reporting was that both  
7 2,4,5-T and 2,4-D was safe for humans.

8 Other events occurring in 1963 give additional  
9 indication of Government knowledge. The Institute  
10 for Defense Analysis wrote a report for the Advanced  
11 Research Project Agency, an agency within the Department  
12 of Defense.

13 This report stated that herbicides were safe  
14 when used commercially but that there could be increased  
15 hazards in military use because greater concentration  
16 would be applied by less experienced personnel under  
17 the pressures that are inherent in battle field use.

18 The report noted the connection between chloracne  
19 and skin and respiratory irritations and their associa-  
20 tions with herbicides.

21 Dr. Key of the Public Health Service testified  
22 at his deposition that in 1963 he placed a sample  
23 of 2,4,5-T herbicide on his forearm to see if it  
24 would induce chloracne. He did this three times a  
25

1  
2 week for three weeks and did develop chloracne on his  
3 forearm.

4 Dr. Key also testified that he had read Kimmig:  
5 and Schulz and learned of Dioxin from that article.  
6 When questioned concerning a June 1964 article by  
7 Dr. Jacob Bleiberg, which discussed chloracne and  
8 pertheoria in workers engaged in 2,4,5-T production  
9 Key stated that he had reviewed the article at the time  
10 it was written and that it was only a more complete  
11 version of what they already knew.

12 Going to the mid or late 1960's, the level of  
13 Government knowledge appears to have increased much  
14 more rapidly during this period. Defendants point  
15 in numerous instances of Government knowledge which  
16 are not disputed by plaintiffs.

17 Dr. Stokinger, the Chief Toxicologist of the  
18 Division of Occupational Health testified that he  
19 knew Dioxin was an impurity in 2,4,5-T sometime  
20 around 1965.

21 (continued on following page.)  
22  
23  
24  
25

HS/ss/2pm/11

2 THE COURT: (Continuing) Colonel Shade,  
3 who is Chief of Chemical Operations Branch of the  
4 Military Service Assistance Command, Vietnam, and later  
5 on the staff of the Chemical Branch of the Assistant  
6 Chief of Staff for Development, testified that he  
7 learned of the connection between Dioxin and 2,4,5-T  
8 sometime between mid-1966 and December of 1968.

9 In July of 1966 the director of the National  
10 Academy of Sciences, wrote to the Chief of the Bureau  
11 of Medicine and Surgery for the Navy, advising him of  
12 a connection between 2,4,5-T and porphyria and chloracne.

13 In August of 1966, the National Academy of Sciences,  
14 in response to a request for information, wrote to the  
15 Army Surgeon General telling him that 2,4,5-T was toxic  
16 and chloracne was associated with it.

17 Recent deposition testimony indicates that people  
18 closely associated with the White House were aware of  
19 hazards involved in the use of defoliants. Dr. Gordon  
20 MacDonald, a member of President Johnson's Science  
21 Advisory Committee, testified that the issues of  
22 herbicides and dioxin in herbicides were informally  
23 discussed by a subgroup of PSAC sometime between April  
24 and June of 1965. Dioxin as an impurity in 2,4,5-T  
25 was also discussed. He said there was discussion of the

1 potential toxicity of dioxin, and while it was con-  
2 sidered that the evidence was fragmentary and in-  
3 conclusive, the subject of dioxin contamination deserved  
4 continuing attention. Dr. MacDonald testified that  
5 human health effects were discussed, and that he attended  
6 a meeting where the effectiveness of herbicides and the  
7 presence of dioxin in 2,4,5-T were discussed. Secretary  
8 of Defense MacNamara, attended this meeting.

9 Dr. Donald Hornig, President Johnson's science  
10 advisor, testified at his deposition that by 1966, the  
11 President's Science Advisory Council was discussing  
12 impurities in 2,4,5-T. He stated that this discussion  
13 occurred sometime between 1964 and 1966. He said that  
14 when he learned of the impurity, he felt that "one  
15 ought to be concerned" about what the magnitudes of the  
16 toxicological effects of the exposures might be. He  
17 testified that he understood it was a health hazard to  
18 human beings. However, it should be noted that he also  
19 testified that he did not relay the information to  
20 President Johnson.

21 An additional element of knowledge is found in a  
22 1967 Rand report commissioned by the Advanced Research  
23 Project Agency of the Department of Defense, which  
24 describes "actual experience" of health hazards  
25 associated with the use of defoliants in Vietnam.

1  
2           Finally, there is the study commissioned by the  
3 National Cancer Institute, called the Bionetics Report.  
4 This study evaluated the carcinogenic, teratogenic and  
5 mutagenic effects of various chemicals. The study was  
6 commissioned in 1063 and the report is dated August  
7 1968. The study did result in a finding of some  
8 teratogenic effects connected with the use of 2,4,5-T.  
9 While it is not clear that defendants are correct that  
10 portions of the study were available to the government  
11 earlier than August 1968, it is clear that by 1968 and  
12 1969, the results of the study were available to the  
13 government.

14           This picture of knowledge shown to be in government  
15 hands is based almost entirely on uncontradicted and  
16 uncontested evidence. It reveals that the government  
17 and the military possessed rather extensive knowledge  
18 tending to show that its use of Agent Orange in Vietnam  
19 created significant, although undetermined risks of  
20 harm to our military personnel. Against this picture we  
21 must examine what what was known by the different de-  
22 fendants, keeping in mind that by and large most of the  
23 government's knowledge was classified and not shared  
24 with the defendants.

25           I will discuss each of the defendants separately.

1           First, as to Dow: Dow supplied Agent Orange to the  
2 military, pursuant to seven contracts. Deliveries were  
3 made from September of 1965 to December of 1968.

4           (continued on following page.)  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25



s/2pm/21

THE COURT: (Continuing) It also supplied the government with Agent Purple, pursuant to three contracts which were probably dated November 1961, December 1962, and May 1963, although the contracts themselves are not available. The government established the specifications for the delivered product, and Dow performed to those specifications.

Dow began manufacturing 2,4,5-T in 1948. Dow admits that it knew prior to this that chloracne was an industrial health hazard present in the production of certain chlorinated hydrocarbons, and it developed the "rabbit ear" test, which was non-specific, but was able to determine if a chloracnegen was present. Dow used this test until 1964.

Undoubtedly, Dow also knew about the explosion at the Monsanto plant in Nitro, West Virginia, in 1949, and the resulting cases of chloracne. Plaintiffs argue persuasively that Dow must have known about it, and Dow does not deny such knowledge.

Moving into the 1950's:

After C.H. Boehringer had the chloracne problems in its plant referred to above, it wrote to Dow for help. In 1955, Dow replied by sending a data sheet describing the hazards due to toxicity and the precautions Dow was taking to prevent them. In 1957, C.H. Boehringer sent

1  
2 Dow information it had learned on how to prepare TCP in  
3 a manner to avoid "chloracne excitors".

4 The Kimmig and Schultz article discussed above  
5 was produced by Dow from its files during discovery.  
6 There is no indication in the record of when Dow obtained  
7 the article, other than the fact that it was referenced  
8 in a memo written by a Dow official in 1964.

9 Plaintiffs argue that Dow knew about the explosion  
10 at the Diamond Alkali plant in 1956, and Dow does not  
11 deny this.

12 Moving into the 1960's:

13 In February of 1964, at Dow's plant in Midland,  
14 Michigan, more than 40 workers developed chloracne.  
15 These workers had been engaged in the manufacture of  
16 TCP. Dow shut down the plant, and its investigation  
17 found that there was a high concentration of chloracnegen  
18 in the waste stream from the plant. Dow determined that  
19 this chloracnegen was dioxin.

20 This incident was reported to the Michigan  
21 Department of Health.

22 Dow developed a method of using gas chromatography  
23 to detect dioxin in TCP and in 2,4,5-T at concentration  
24 levels as low as one part per million. This is followed  
25 by the usual designation (ppm). Dow researchers

1  
2 determined that there was no chloracnegenic response if  
3 the dioxin level was at or below one ppm. Dow thereupon  
4 instituted precedures to ensure that no TCP or 2,4,5-T  
5 left the plant with a dioxin level above one ppm. Dow's  
6 exhibits 42 through 45 indicate that Dow's dioxin  
7 levels in its 2,4,5-T were less than one ppm, but these  
8 exhibits do not appear to cover all of the 2,4,5-T  
9 and Agent Orange Dow produced. However, plaintiffs  
10 do not, as I recall, challenge Dow's contention that its  
11 2,4,5-T was contaminated by one ppm of dioxin or less.  
12 Since Agent Orange was a 50-50 mixture of 2,4,5-T with  
13 2,4-D, and since plaintiffs have abandoned their earlier  
14 claims against 2,4-D, this in effect establishes for  
15 purposes of this motion a contamination level for Dow's  
16 Agent Orange at .5 ppm or less.

17 In March 1965, Dow called a meeting attended by  
18 Hercules, Diamind Shamrock, and Hooker to discuss the  
19 health hazards involved in the production of TCP and  
20 2,4,5-T. No one from the government was invited to the  
21 meeting, but Dow had not yet contracted to produce  
22 Agent Orange. It is not disputed that Dow knew that  
23 the dioxin problem arose during the manufacturing process  
24 and that any dioxin produced at that stage could carry  
25 forward into the delivered product. At the meeting,

1  
2 Dow explained that precautions were necessary to  
3 prevent health hazards, and stated that it had examined  
4 herbicides sold by some other companys and found some  
5 to contain "surprising high levels" of dioxin.

6 It should be noted that in a memo to the file  
7 after the March 1965 meeting, Chandler of Diamond  
8 indicated that Dow thought that repeated exposure to  
9 one ppm could be dangerous.

10 In June of 1965, V.K. Rowe of the Dow biochemical  
11 research laboratory wrote to Ross Mulholland of Dow  
12 Chemical of Canada. He described the chloracne problems  
13 Dow had experienced and stated thatDow did not want any  
14 of its customers to develop acne. The letter also  
15 indicated a fear of government intervention into and  
16 control of the entire herbicide industry, and that Dow  
17 wanted to get the problem under control without govern-  
18 mental regulation. Mulholland was cautioned not to  
19 transmit this information to anyone else.

20 There are four items which Dow claims show that  
21 it transmitted information concerning health hazards  
22 to the government:

23 The first was a February 29, 1967 letter from A.P.  
24 Beutel, vice president of Dow, to General Hebbeler  
25 concerning the government's plan for producing Agent

1  
2 Orange. Beutel mentions "certain health problems"  
3 inherent in the manufacturing process.

4 The second was an April 20, 1967 letter of Beutel  
5 to H.G. Fredricks, concerning the proposed government  
6 production of Agnet Orange. Beutel mentions a "serious  
7 potential health hazard" to workers, and states that  
8 even with detection methods, care is necessary in the  
9 handling of the product.

10 The third occurred in August, 1967, when Beutel  
11 and two other Dow representatives told two officials  
12 from the office of the Secretary of Defense that caution  
13 should be exercised in producing 2,4,5-T.

14 The fourth was on September 27, 1967, when Beutel  
15 wrote to the government indicating that Dow would not  
16 bit on the government project because of the chloracne  
17 problem, among other factors.

18 In March, 1970, Dow briefed representatives of  
19 the military on the presence of dioxin as an impurity  
20 in PCP and 2,4,5-T. By this time, there appears to  
21 have been widespread concern in various sectors of the  
22 government concerning the hazards of defoliation program.

23 In June 1970, after temporary suspension of Agent  
24 Orange use, Dow wrote to Secretary of Defense Melvin  
25 Laird recommending "strongly" that the government set

1  
2 appropriate specifications and controls to insure that  
3 no 2,4,5-T be used if it contained more than one ppm  
4 dioxin, and Dow specifically urged that standard for  
5 any 2,4,5-T used as a component of Agent Orange, if it  
6 was to be used as a defoliant in Vietnam.

7 If there is a real difference of the level of  
8 knowledge between Dow and the government, it focuses  
9 upon Dow's discovery in 1964 that dioxin was the  
10 chloracneagen in TCP, its development of a test to  
11 determine dioxin levels, and its development of techniques  
12 obtained partially through purchase from C.H. Boehringer  
13 to reduce the dioxin levels during the manufacturing  
14 process. One question of fact is whether this knowledge,  
15 if disclosed to the government, would have made a  
16 difference in the government's decision making process  
17 about the use of Agent Orange.

18 Related questions of fact are the actual dioxin  
19 levels in Dow's product and the actual hazards involved  
20 in the use of the products at different levels of dioxin.

21 A lot of this boils down to whether or not one ppm  
22 is or was safe. Arguably, if Dow was selling a clean  
23 "safe" product to the government, then it told the  
24 government everything it needed to know. Of course,  
25 if the product was clean and safe, Dow would win on the

1 causation issue, too, because a clean and safe herbicide,  
2 by definition, would not cause the injuries plaintiffs  
3 claim to have suffered from Agent Orange.

4 (continued on following page.)  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

1  
2 Next, Thompson-Heyward, T-H supplied the  
3 government with Agent Orange pursuant to contracts dated  
4 June 28, 1967, March 1, 1968, and May 20, 1968.

5 T-H had manufactured 2,4,5-T for commercial  
6 sale as a herbicide prior to 1967. It did not make  
7 TCP but rather purchased it from other chemical  
8 companies.

9 T-H's first knowledge of any problems associated  
10 with 2,4,5-T occurred in 1964. In December of that  
11 year, Dr. Groth of the Public Health Service wrote  
12 to T-H requesting samples of 2,4,5-T. The letter  
13 stated that 2,4,5-T was associated with chloracne and  
14 that it was suspected that dioxin was the culprit.  
15 Groth stated that he was attempting to develop a  
16 method to isolate the contaminant. T-H claims  
17 that this was the first time it learned of such  
18 problems.

19 In December 1964, DeAtley, a vice president  
20 of T-H, wrote to Dr. Dosser, the laboratory director  
21 at Dow, telling him of Grother's letter. Dosser  
22 replied in a telephone call that there might be some  
23 methods of production which led to a toxic compound.  
24 In January 1965, DeAtley concluded that T-H should  
25 conduct some tests of its own.



1  
2           At this time T-H was not yet a government  
3 supplier of Agent Orange.

4           On February 19, 1965, DeAtley and Fuhlhage of  
5 T-H visited Dow's Midland plant. The minutes of the  
6 meeting indicate that DeAtley and Fuhlhage learned  
7 that cases of chloracne had recently been more severe,  
8 and that Dow had its workers changing clothing and  
9 showing at mid-shift.

10           T-H admits that it had cases of chloracne  
11 among its workers, but claims that it did not know  
12 the cause until December 1964 at the earliest. T-H's  
13 point is that by June 1967 when it first became a  
14 government contractor, the government certainly knew  
15 as much as it did.

16           1       In June 1967, when T-H negotiated its first  
17 contract, it did tell the government that there was  
18 a chloracne problem in the manufacturing process and  
19 that this was factored into the price.

20           The level of dioxin in T-H's Agent Orange is  
21 not clear. According to plaintiffs, T-H has not  
22 turned over its books recording levels of dioxin,  
23 except for 1970 and 1971. Samples tested at Gulfport  
24 indicate a level that went as high as 4.1 ppm which  
25 raises a question of fact as to its harmful potential.

1  
2           Plaintiffs emphasize the fact that T-H knew  
3 that gas chromatography could determine dioxin level,  
4 but never told the military about it even after it  
5 began to supply Agent Orange to the government.  
6 Nor did it tell the government that its chloracne  
7 manufacturing problem was probably caused by dioxin,  
8 or that the contaminant very likely carried over  
9 into the delivered Agent Orange.

10                   (Continued on following page)

11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

SS/an  
3pm/2

1  
2 Uniroyal, Inc. sold Agent Orange to the  
3 government pursuant to three contracts between October  
4 6, 1966 and March 1, 1968. It appears to be  
5 undisputed that the product it sold was not  
6 manufactured by Uniroyal, Inc., but rather, was  
7 supplied to Uniroyal, Inc. by a Canadian subsidiary  
8 now named Uniroyal, Ltd. Inc. denies having had any  
9 knowledge of the toxicity of 2,4,5-T or that there  
10 were any health hazards connected with Agent Orange.  
11 Uniroyal has not presented evidence of the actual level  
12 of dioxin contamination of its product.

13 The sole "definitive evidence" of Uniroyal,  
14 Inc.'s knowledge of chloracne problems is found in a  
15 memo from Uniroyal, Ltd. to Uniroyal, Inc. dated  
16 June 11, 1962, which states that five employees at  
17 the Clover Bar plant had symptoms of chloracne. A  
18 reply affidavit of Arthur Gorman, technical liaison  
19 to the Uniroyal, Ltd. plant at the time, states  
20 that the Clover Bar facility did not produce  
21 either TCP or 2,4,5-T in 1962. The inference  
22 is that this memo has nothing to do with this case.

23 There are at least two issues of fact with  
24 respect to Uniroyal, Inc. which preclude summary  
25 judgment in its favor. The first concerns the memo

1  
2 of T. H. Evans of Uniroyal, Ltd. dated August 10,  
3 1965. That memo was found in the files of  
4 Walter Harris of Uniroyal, Inc. who stated that  
5 he did not receive it until 1968. Evans stated  
6 in his affidavit that he did not send it to Uniroyal,  
7 Inc., and Arthur Gorman of Uniroyal, Ltd. also stated  
8 that copies of the Evans memo were not sent to Uniroyal  
9 until 1968. Just when Uniroyal, Inc. received it,  
10 however, presents a triable issue of fact.

11 The memo is important because it contains  
12 Evans' description of his visit to Dow's Midland plant  
13 in 1965 and discussions of chloracne problems and  
14 dioxin. If the jury were to find that Uniroyal,  
15 Inc. knew a lot more than it claimed it knew when  
16 it entered into its first contract with the government  
17 in 1966.

18 The second issue of fact is whether Uniroyal,  
19 Inc. is chargeable with the knowledge of its  
20 subsidiary, Uniroyal, Ltd., because of the corporate  
21 relationship. Assuming without deciding the  
22 validity of Uniroyal, Inc.'s argument that there is  
23 a presumption of separateness, I do not fault  
24 Uniroyal, Inc. for its irritation at plaintiffs'  
25 eleventh hour argument here.

1  
2 I do not think, however, that plaintiffs' or  
3 Uniroyal's cross-claiming co-defendants should be  
4 permitted to introduce evidence, if they can,  
5 that the two corporations were really the same  
6 entity. If the parties intend to pursue that line  
7 I expect that they will be doing so in good faith  
8 and not just wasting the court's time or attempting  
9 to confuse the issues.

10 Riverdale states that it manufactured Agent  
11 Orange pursuant to a contract, that the government  
12 set the specifications, that it performed to specifica-  
13 tions, and that it knew of no health hazard connected  
14 with Agent Orange.

15 Riverdale's motion for summary judgment is  
16 unopposed, except by its co-defendants who argue merely  
17 that it is too early to grant summary judgment for  
18 Riverdale. However, as Riverdale points out in its  
19 reply memorandum, opposition to a summary judgment  
20 motion "must set forth specific facts showing  
21 that there is a genuine issue for trial."

22 FRCP 56(d). The party opposing summary  
23 judgment must offer "some competent evidence that could be  
24 presented at trial showing that there is a genuine  
25 issue as to a material fact."

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

No such evidence has been presented, and there are no other circumstances as to why summary judgment can't be fairly granted now.

Hoffman-Taff is in the same situation as Riverdale, and for the same reasons is entitled to summary judgment in its favor.

(continued on following page.)

1874 3/3

1  
2 Originally, Thompson declined to bid for Agent  
3 Orange contracts. Acting under appropriate statutory  
4 authority, however, the government required Thompson  
5 to supply Agent Orange pursuant to two contracts,  
6 dated April 19, 1967 and May 24, 1968. It supplied  
7 333, 685 gallons between September 1967 and January  
8 1969. As reflected in test results, the dioxin  
9 content of its product ranged from .10 to .3 ppm.

10 There is no evidence that Thompson knew of  
11 any toxicity problems associated with the use of  
12 any of its products up to the time that the government  
13 required it to produce Agent Orange. Thompson  
14 himself testified that he had never heard of dioxin  
15 until recently.

16 Soon after it began to manufacture Agent  
17 Orange, Thompson experienced an incident that caused  
18 a few of its employees to develop what was believed  
19 to be chloracne. The principal evidence of Thompson's  
20 knowledge of this health hazard is found in an  
21 internal memo of Dow Chemical Company dated February  
22 1967. A Mr. Buckley, now deceased, of Thompson,  
23 requested information from Dow to assist him in  
24 dealing with a "severe chloracne problem" with some  
25 of their employees. The second memo, written by

1  
2 V.K. Rowe, indicates that he did not give Buckley  
3 a very detailed description of what caused the problem  
4 because, in his words, "It was quickly apparent that  
5 Mr. Buckley had little understanding of the  
6 toxicological aspects of his problem. Had he asked  
7 for methods, etc., I would have agreed to send them  
8 to him."

9           There is no claim that Thompson disclosed this  
10 production accident to the government; however,  
11 the government already knew of similar and more  
12 serious problems that had occurred at Monsanto and  
13 Diamond, and, possibly, the government knew of Dow's  
14 1964 chloracne problem.

15           At most, this incident establishes Thompson's  
16 knowledge of possible health hazards related to the  
17 manufacture of Agent Orange. It establishes no  
18 knowledge in Thompson of hazards to users. Plaintiffs  
19 would have me infer such knowledge, perhaps even  
20 infer that the problem was discussed in the telephone  
21 conversation between Buckley and Rowe. The evidence  
22 presented, however, does not support the inference  
23 but instead invites mere speculation, particularly  
24 when we consider that the deceased Mr. Buckley would  
25 be unavailable to testify.



3  
1  
2 On the other side of the knowledge comparison,  
3 it is clear that by 1967, when Thompson first  
4 contracted to manufacture Agent Orange, the government  
5 had a significant amount of knowledge about dioxin,  
6 its contamination of 2,4,5-T, and its association  
7 with chloracne and some other health problems.  
8 Without question, the government's level of knowledge  
9 greatly exceeded that of Thompson in 1967.

10 Plaintiff also argues that Thompson had  
11 knowledge of and the discretion to use alternative  
12 methods of manufacturing Agent Orange. Thompson  
13 points out that there is no evidence to support that  
14 assertion. Even assuming it to be true, however,  
15 there is no evidence that Thompson knew of any risk  
16 to users that would call for the use of an alternative  
17 manufacturing method, and Thompson itself denies  
18 knowledge of any such risk.

19 Under these circumstances, I conclude that  
20 Thompson has established that there is no issue of  
21 material fact remaining for trial on the government  
22 contract defense, and that Thompson is therefore  
23 entitled to summary judgment.

24 Hercules supplied compounds containing 2,4,5-T  
25 pursuant to 15 contracts dating from May 8, 1964

1  
2 through May 20, 1968.

3           There is no evidence in the record that  
4 Hercules knew anything concerning chloracne or other  
5 health problems related to the production of 2,4,5-T  
6 during the 1940s or 1950s. Dr. Frawley, Hercules'  
7 general manager of Health, Environment and Safety,  
8 who has been with Hercules since 1956, testified  
9 at his deposition that he did not learn of Monsanto's  
10 1949 chloracne problems until February 1965. With  
11 respect to Diamond Alkali's explosion in 1956,  
12 Frawley testified that he knew of the explosion  
13 but not of the toxicity associated with it.

14           Hercules began producing phenoxy herbicides in  
15 1961. In 1964, it began to manufacture Agent Orange  
16 under contracts with the U.S. Government.

17           Frawley of Hercules wrote to V.K. Rowe of  
18 Dow on July 3, 1963 concerning a request by Dr. Leary  
19 of the United States Department of Agriculture that  
20 the chemical companies do some testing of phenoxy  
21 herbicides. Plaintiff contends that this letter  
22 is evidence of Hercules' knowledge of the problems  
23 associated with 2,4,5-T. However, as Frawley  
24 points out in his answering affidavit, the few  
25 problems of alleged health hazards mentioned in the

5  
1  
2 letter relate to 2,4-D, not to 2,4,5-T.

3 Frawley states that the first knowledge he had  
4 of industrial health problems associated with the  
5 production of 2,4,5-T occurred in February 1965, when  
6 he was told by Dow of their chloracne problem. In  
7 March 1965, Frawley attended the Dow meeting (discussed  
8 above), where he received Dow's analyses of Hercules'  
9 product. They showed a very low level of dioxin.

10 Later in 1965, Hercules improved its process  
11 of production so as to eliminate even the low dioxin  
12 level, and Hercules began to test its own product  
13 for dioxin contamination.

14 From January 1966 through May 1970 Hercules'  
15 product contained no measurable dioxin except in  
16 September 1966 when it measured .1 ppm.

17 (Continued on following page)  
18  
19  
20  
21  
22  
23  
24  
25

urms 4pml

1  
2           The results of U.S.D.A. tests in 1970 also  
3 howed no measurable dioxin. Nor do plaintiffs  
4 seriously contend that Hercules' product was  
5 contaminated by any significant amounts of dioxin.

6           With the exception of the inconclusive  
7 incidents involving two children who ate sprayed  
8 fruit and the workers who worked in a sprayed area,  
9 plaintiffs present no concrete evidence of Hercules'  
10 knowledge of any problems prior to March 1965.

11           Frawley states in his affidavit that to his  
12 knowledge Hercules never had a case of chloracne  
13 among its workers from 1961 until 1970 when it  
14 ceased production. Further, he states that Hercules  
15 learned of possible teratogenicity only in 1969 when  
16 the government released the Monetics report.

17           Under the heading discussion.

18           In pretrial order No.33 dated February 24, 1982,  
19 I defined the government contract defense as follows:

20           A defendant in this case will be entitled  
21 to judgment dismissing all claims against  
22 it based on that defendant's having supplied  
23 "Agent Orange" to the government pursuant  
24 to a contract, if the defendant proves:

25           1. That the government established the

1  
2 specifications for "Agent Orange";

3 2. That the "Agent Orange" manufactured by the  
4 defendant met the government's specifications  
5 in all material respects; and

6 3. That the government knew as much as or more  
7 than the defendant about the hazards to people  
8 that accompanied use of "Agent Orange".

9 Each defendant has established the first two  
10 elements of the defense. Consequently, pursuant to  
11 Federal Rules of Civil Procedure 56(d), I have  
12 determined that there is no substantial controversy  
13 with respect to any defendant over those two facts  
14 which shall be deemed established for purposes of  
15 the trial of this action. But these are the only  
16 two facts I am determining for future purposes. All  
17 other discussion of facts and evidence in this decision  
18 relates only to these summary judgment motions.

19 Plaintiffs argued with considerable force that  
20 because defendants did not share with the government  
21 all their knowledge about Agent Orange, the resulting  
22 ignorance on the government's part affected not only what  
23 was put into or omitted from the specifications  
24 but also the standards applied to determine whether  
25 a particular defendants' product conformed to the

1  
2 specifications. I view this more as a means of talking  
3 about the central problem of knowledge, then as a  
4 proper description of the elements of the government  
5 contract defense. For purposes of that defense and  
6 its analysis, the various problems arising out of  
7 differing level of knowledge between the government  
8 and the defendants are encompassed in the third  
9 element.

3 10 (Continued on following page)

11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

HR/an  
4pm/2

1  
2 With respect to that third element -- whether  
3 the government knew as much or more than the defendant  
4 about the hazards to people that accompanied  
5 use of Agent Orange -- four of the defendants,  
6 Riverdale, Hoffman-Taff, Thompson, and Hercules,  
7 have established that there is no triable  
8 issue and each of them is entitled to judgment  
9 dismissing all complaints, and all cross-claims  
10 against them on the ground that the government  
11 contract defense shields them from liability.

12 As to all four of these defendants there is  
13 no triable issue over knowledge. As to each, on the  
14 record before the Court the government clearly  
15 knew as much as or more than the defendant about  
16 any hazards to people that accompanied use of that  
17 defendant's product.

18 Riverdale and Hoffman-Taff both deny any  
19 knowledge of hazards, and no other party has  
20 controverted their denials. Thompson was essentially  
21 an unwilling producer of Agent Orange who knew  
22 virtually nothing about its hazards.

23 Clearly, in 1967 when it first began to supply  
24 the herbicide, the government's knowledge of the  
25 hazards of Agent Orange exceeded that of Thompson.

1  
2 Hercules' dismissal rests on the same ground, but  
3 follows for different reasons. Unlike Riverdale,  
4 Hoffman-Taff and Thompson, Hercules was aware of  
5 possible Dioxin contamination of 2,4,5-T.

6 But since the Agent Orange produced by Hercules  
7 was free of the contamination, there was no  
8 Dioxin-related hazards accompanying its product about  
9 which Hercules could have had knowledge.

10 Summary judgment is denied with respect to  
11 Dow, Thompson-Hayward and Uniroyal, Inc. on the ground  
12 that on the papers before the Court triable issues  
13 of fact are presented on the question of relative  
14 knowledge. Following our earlier schedule, this  
15 would have meant that the trial of the government  
16 contract defense would proceed for these defendants  
17 together with Monsanto and Diamond on June 27th.

18 However, for a combination of reasons I have  
19 concluded that a separate trial of what remains of the  
20 government contract defense with respect to the  
21 remaining defendants is no longer appropriate.

22 It might prejudice the plaintiffs by  
23 over-emphasizing the importance of this  
24 narrowly drawn defense as it has evolved in its  
25 present context: it might prejudice the defendants



1  
2 by requiring presentation of the issue on hypothetical  
3 questions of causation that ultimately would have  
4 to be developed on a full record; and it would  
5 prejudice both sides due to the additional time,  
6 effort and expense that would be required.

7 (continued on following page.)  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

HR/ss/4pm/31

2 THE COURT: As this case has developed we all have  
3 learned a lot. In 1980 when I entered an order anti-  
4 cipating phased trials, the idea of a separate trial of  
5 the fact issues raised by the government contract de-  
6 fense seemed appealing. It had the advantages of  
7 focusing on what appeared to be a discrete segment of  
8 the evidence with a possible early termination of the  
9 lawsuit, and a saving to all parties of considerable  
10 unnecessary expense. The chief disadvantage of the  
11 separate trial appeared to be a relatively insignificant  
12 one of having to assume hypothetically certain facts  
13 about liability. ~~On balance, the goals of obtaining a~~  
14 just, speedy, and inexpensive determination seemed to  
15 be well served by working toward a separate trial of the  
16 government contract defense. The premise underlying that  
17 conclusion was that the elements of the defense would  
18 be uniquely suited to consideration of adjudication,  
19 separately and apart from the issues of liability,  
20 general causation, and damages. In addition, it seemed  
21 to me at the time that as a practical matter discovery  
22 on those discrete issues would be rather narrow compared  
23 to the discovery that some of the other fact issues  
24 presented by this action might require.

25 What has actually happened, however, is that, as

1  
2 we all have learned more about the development and use  
3 of Agent Orange in Vietnam, the issues in the action  
4 have become clearer. Plaintiffs undoubtedly will  
5 strongly emphasize a negligent failure to warn as a  
6 bias for liability. But when the "knowledge" factor  
7 of the government contract defense is placed alongside  
8 a liability theory of a negligent failure to warn, the  
9 issues, unfortunately, no longer remain discrete or  
10 separate. On the contrary, they tend to merge, and so  
11 much so that the legal test for liability under a failure  
12 to warn negligence theory would fully encompass all  
13 the knowledge issues of the government contract defense  
14 except for the final test of whether the knowledge "would  
15 have" as opposed to "might have" affected the military's  
16 handling of Agent Orange purchases and use.

17 Separate application of the government contract  
18 defense has been possible as to the four defendants in  
19 whose favor I will be granting summary judgment. As to  
20 the remaining defendants, however, the central point  
21 of the dispute seems to have shifted. Plaintiffs'  
22 claim is that dioxin is extremely toxic, that it was  
23 produced as a by-product in the manufacture of TCP  
24 which was a precursor chemical for 2,4,5-T which in turn  
25 was combined with 2,4-D to make Agent Orange. Any dioxin

1  
2 produced in the manufacturer of TCP carried forward  
3 into 2,4,5-T and therefore into the Agent Orange.

4 Whether or not the presence of a dioxin contaminant  
5 in Agent Orange gives rise to liability is complicated  
6 by a variety of circumstances, including the relative  
7 ignorance of virtually everyone about dioxin when our  
8 involvement in Vietnam commenced, the increasing level  
9 of everyone's knowledge about dioxin at varying rates  
10 until Agent Orange was no longer used in Vietnam, the  
11 changing level of technology which enabled the scientist  
12 to detect and measure smaller and smaller concentrations  
13 of dioxin over the relevant time period, and the dynamic,  
14 constantly changing attitudes of the military and  
15 political authorities about the use in Vietnam of herb-  
16 icides.

17 The problem is illuminated by comparing the  
18 situation of Hercules with that of Dow. Hercules attended  
19 the 1965 meeting called by Dow to consider the problem  
20 of dioxin contamination in 2,4,5-T. Beginning January  
21 1966, the 2,4,5-T produced by Hercules was, with one  
22 exception, free of any detectable dioxin. This meant  
23 that if dioxin was present, it was there in concen-  
24 trations of less than one tenth of one part per million.  
25 In one month out of the ensuing 39 months of production,

2 Hercules' 2,4,5-T did show dioxin contamination, but  
3 at minimum measurable level: .1 ppm. Under all these  
4 circumstances Hercules had no knowledge of harm from  
5 dioxin contamination caused by its product, because its  
6 product was free of such contamination. The one month  
7 when a trace was found becomes de minimis when compared  
8 with the dioxin contained in the other companies'  
9 products. Since Hercules had no knowledge of its product  
10 creating hazards to people, its knowledge could not  
11 have exceeded that of the government, and it therefore  
12 has established the third element of the government  
13 contract defense, thereby entitling Hercules to summary  
14 judgment in its favor.

15 Dow took a different approach to its production  
16 than Hercules. Instead of producing a dioxin-free  
17 product, it adopted a self-imposed contamination standard  
18 of one ppm for its 2,4,5-T. At the March 1965 meeting,  
19 Dow urged the others in attendance to adopt that single  
20 standard and to use it as the industry standard for  
21 2,4,5-T. From the evidence in the present record Dow  
22 believed that standard to be within a reasonable margin  
23 of safety so that hazards to people would be eliminated.  
24 The test results in the record show that neither Diamond  
25 nor Monsanto followed Dow's recommendation. Dow itself

1  
2 lived up to its self imposed standard, however, with  
3 the result that the Agent Orange it produced contained  
4 .5 ppm. It may eventually appear that the 1 ppm standard  
5 was safe. If so, then Dow could succeed in its government  
6 contract defense, just as Hercules has now done by show-  
7 ing the safety of its product. It could also succeed  
8 against any liability claim based on an allegedly  
9 defective product. We do not know whether Dow's self  
10 imposed 1 ppm standard was a safe level for dioxin con-  
11 tamination of the 2,4,5-T. Indeed, we do not know  
12 whether contamination even at the level of 140 ppm,  
13 the highest level for any product given at any time in  
14 the papers now before the court, would produce Agent  
15 Orange that was hazardous to people. This, the 1 ppm  
16 standard raised an issue of fact that precluded summary  
17 judgment in its favor.

18 It may also eventually appear that if Dow had  
19 revealed its concerns about dioxin to the government in  
20 1965 the military would have adopted that standard  
21 regardless of what our present knowledge tells us about  
22 the safety of that standard. In that event, Dow would  
23 succeed against a claim of negligent failure to warn,  
24 but not on its government contract defense. Rather, it  
25 would succeed on the causation issue, because Dow's

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

failure to disclose its concerns about dioxin would not have affected the military's judgment in using the product.

If we were to proceed at this time with a separate trial of the government contract defense as to those defendants who remain in the case, we would on that trial have to determine whether dioxin contamination of Agent Orange was harmful, if so, in what concentration did it become harmful, and finally, if the defendant's product was unsafe and if the defendant had told the military in 1965 of Dow's fears about the effect of dioxin contamination, might the military have stopped using Agent Orange, changed its specifications to provide a maximum level of contamination, changed its method of using Agent Orange in the field or imposed safety precautions in connection with its use in the field.

(continued on following page.)

18 5pml

1 THE COURT: (Continuing) A trial to answer  
2 these questions would necessarily involve most of the  
3 evidence needed for trial of the issues relating  
4 to liability and general causation. Under these  
5 circumstances I conclude that justice would be  
6 served by combining what remains of the government  
7 contract defense issues with a trial on liability  
8 and general causation which will be scheduled after  
9 completion of the remaining discovery necessary for  
10 those issues.

11 In the general context of case management  
12 for the future, I will continue the action under the  
13 supervision of the Special Master, Sol Schreiber,  
14 who has thus far provided extraordinary, even  
15 heroic, assistance in bringing the case this far.  
16 His authority will continue as before, with the  
17 objective being a trial at the earliest reasonable  
18 date covering the issues of liability, general  
19 causation, and the government contract defense.  
20 I will request the Special Master to recommend an  
21 appropriate timetable for the remaining discovery,  
22 any further motions, preparation of a pretrial order,  
23 and for the trial. I will also request from him,  
24 as quickly as possible, a formal recommendation  
25 with respect to the nature and form of class



1  
2 certification. Despite the determined resistance  
3 by some of the dismissed defendants, I will nevertheless  
4 in the interest of justice defer entry of summary  
5 judgment on the present motions until after the class  
6 has been certified. As a kindness to my colleagues  
7 in the Second Circuit, I suggest to defendants that  
8 as soon as possible you tell them of whatever parts  
9 of your mandamus petitions you wish to withdraw on  
10 grounds of mootness.

11 A question has been raised as to the pending  
12 status and circumstances with respect to intervention  
13 by the additional plaintiffs, which I discussed with  
14 you at an earlier date. When the problem was brought  
15 up, plaintiffs offered to have all their known  
16 potential plaintiffs intervene in the option, and  
17 they offered to do this, as I understood it, for the  
18 purpose of blending possibly even destroying any  
19 claims of prejudice by the defendants that might  
20 have arisen from a deferral of class certification  
21 until after the trial on the government contractor  
22 defense. We are all aware of many of the problems  
23 that relate to the problem of class certification  
24 in an action of this type. I took at face value  
25 plaintiffs' representation of their willingness to

1  
2 intervene. I granted permission to do so. There  
3 have been so misunderstandings with respect to the  
4 form and place of intervention, and in light of that  
5 I have extended the time of the plaintiffs to do so  
6 for an additional two weeks. In light of some  
7 questions that have been asked, I should state --  
8 although it seems to evident to me -- that I have no  
9 power to require anyone to intervene in the action.  
10 Nevertheless, it would greatly facilitate the future  
11 course of the action, if the intervention plan was  
12 carried through by the plaintiffs as they represented  
13 they would do so weeks so.

14 I have a couple of additional points:

15 I am going to ask the Special Master to reconsider  
16 with counsel whether the need for secrecy about the  
17 papers in this case still remains. I'd like him to  
18 consider whether some of the restrictions on public  
19 disclosure of the affidavits, documents and depositions  
20 cannot be lifted. From what I have seen on television  
21 and from what I have read in the newspapers, it appears  
22 that some counsel and some parties in this case  
23 don't take seriously either their ethical obligations  
24 or the orders of this Court with respect to disclosure  
25 of information. I have more important things to do,

1  
2 I think, than to police such problems. I do under-  
3 stand that due to a careless designation on the  
4 filing of some papers in the action, some information  
5 which was intended to be under seal ended up in the  
6 hands of a newspaper reporter. However, other  
7 documents as to which there have been no slip-ups  
8 in filing or designation for sealing, have also been  
9 quoted directly in newspaper articles. This simply  
10 confirms my own view that in the circumstances of  
11 this case, as with many others, it is futile to attempt  
12 to keep information confidential.

13 Although keeping discovery materials subject  
14 to the protective order previously granted in this  
15 case has already served several worthwhile purposes,  
16 I am not certain that those purposes are furthered  
17 by continuing the sealing with respect to the motion  
18 papers on these summary judgment motions. I request  
19 the Special Master to review the matter again with  
20 counsel and make an appropriate recommendation to me.

21 Finally, a word as to why I requested the  
22 Special Master to stop the depositions that were  
23 scheduled for this week. When I learned that there  
24 were several depositions scheduled to take place in  
25 various parts of the country, I became concerned over

5  
1 the unnecessary expense that those depositions would  
2 cause for some of the parties, and the extra expense  
3 and inconvenience that the accelerated deposition  
4 schedule would impose on other parties. I was also  
5 acutely aware of the tension and anxiety that the  
6 rapidly approaching trial date was generating in  
7 all concerned. As a result, once I reached the  
8 conclusion that a separate trial of the government  
9 contract defense for the remaining defendants would  
10 not further the interests of justice, I felt it  
11 appropriate to put a hold on the depositions until  
12 you could hear the full details of this decision.  
13 There will be ample time for the remaining defendants  
14 to reschedule the cancelled depositions and to readjust  
15 their schedules to conform to the new trial date.

16 Mr. Schreiber, the Special Master, has asked  
17 me to tell you that he will meet with counsel here,  
18 next Monday at 2:00 o'clock, in order to discuss  
19 further steps in this case.

20 I thank you very much.

21 (Whereupon, the proceedings were concluded)  
22  
23  
24  
25

1

2

3

C E R T I F I C A T I O N

4

5

I, HARRY RAPAPORT, a Court Reporter for the  
Eastern District of New York, hereby  
certify the foregoing transcript as being true  
and accurate.

6

7

8

9

10

11



HARRY RAPAPORT

12

13

14

15

16

17

18

19

20

21

22

23

24

25